Wang, Wanrui2024-02-262024-02-262022-04https://hdl.handle.net/11299/261416Faculty Mentor: Carston R. WagnerVascular normalization involves the use of anti-angiogenic therapeutics to restore proper tumor oxygenation and perfusion to improve the effectiveness of anti-cancer therapeutics. The VEGFR played a vital role in cancer by promoting neovascularization for continuing tumor growth. The VEGFR2 protein is expressed and purified with IMAC and SEC and evaluated with flow cytometry. The Ability of VEGFR2 CSANs to Inhibit VEGF Induced Signaling and Proliferation is determined with enzyme-linked immunosorbent assay (ELISA) and IncuCyte. Consistent with the hypothesis, the VEGFR2-16 affibody was expressed and oligomerized successfully into CSANs, and the ability of targeting was determined.Presentation